Current Filters

Showing 41 - 50 results of 3488

Ocriplasmin (Jetrea) (Last Updated: Jun 6, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Jetrea
Manufacturer:
Alcon Canada Inc.
Submission Type:
Initial
Indications:

Vitreomacular adhesion

Canagliflozin (Invokana) (Last Updated: Jun 5, 2013)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Invokana
Manufacturer:
Janssen Inc.
Submission Type:
Initial
Indications:

Diabetes mellitus, type 2

Somatropin (Genotropin) (Last Updated: May 27, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Genotropin
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Turner Syndrome

Somatropin (Genotropin) (Last Updated: May 27, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Genotropin
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Growth hormone deficiency, pediatric

Somatropin (Genotropin) (Last Updated: May 27, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Genotropin
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Growth hormone deficiency, adult

Lurasidone (Latuda) (Last Updated: May 9, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Latuda
Manufacturer:
Sunovion Pharmaceuticals Inc.
Submission Type:
Resubmission
Indications:

Schizophrenia

Saxagliptin (Onglyza) (Last Updated: May 9, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Onglyza
Manufacturer:
Bristol-Myers Squibb / AstraZeneca Canada Inc.
Submission Type:
Initial
Indications:

Diabetes mellitus (Type 2)

Ingenol mebutate (Picato) (Last Updated: May 9, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Picato
Manufacturer:
LEO Pharma Inc.
Submission Type:
Initial
Indications:

Keratosis, actinic

Ulipristal acetate (Fibristal) (Last Updated: Apr 17, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Fibristal
Manufacturer:
Actavis Specialty Pharmaceuticals Co.
Submission Type:
Initial
Indications:

Uterine fibroids (signs and symptoms)

Rivaroxaban (Xarelto) (Last Updated: May 6, 2013)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Xarelto
Manufacturer:
Bayer Inc.
Submission Type:
Initial
Indications:

Thromboembolic events (venous), pulmonary embolism

Download results as CSV